Castle Biosciences Net Worth
Castle Biosciences Net Worth Breakdown | CSTL |
Castle Biosciences Net Worth Analysis
Castle Biosciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Castle Biosciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Castle Biosciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Castle Biosciences' net worth analysis. One common approach is to calculate Castle Biosciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Castle Biosciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Castle Biosciences' net worth. This approach calculates the present value of Castle Biosciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Castle Biosciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Castle Biosciences' net worth. This involves comparing Castle Biosciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Castle Biosciences' net worth relative to its peers.
To determine if Castle Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Castle Biosciences' net worth research are outlined below:
| Castle Biosciences generated a negative expected return over the last 90 days | |
| Castle Biosciences has high historical volatility and very poor performance | |
| Over 94.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Castle Biosciences at KeyBanc Forum Strategic Insights for 2025 By Investing.com - Investing.com UK |
Castle Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Castle Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Castle Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Castle Biosciences Target Price Consensus
Castle target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Castle Biosciences' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 9 | Strong Buy |
Most Castle analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Castle stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Castle Biosciences, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationCastle Biosciences Target Price Projection
Castle Biosciences' current and average target prices are 20.07 and 41.56, respectively. The current price of Castle Biosciences is the price at which Castle Biosciences is currently trading. On the other hand, Castle Biosciences' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Castle Biosciences Market Quote on 21st of March 2025
Target Price
Analyst Consensus On Castle Biosciences Target Price
Know Castle Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Castle Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Castle Biosciences backward and forwards among themselves. Castle Biosciences' institutional investor refers to the entity that pools money to purchase Castle Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Renaissance Technologies Corp | 2024-12-31 | 685 K | Geode Capital Management, Llc | 2024-12-31 | 628.2 K | Millennium Management Llc | 2024-12-31 | 548.8 K | Point72 Asset Management, L.p. | 2024-12-31 | 547.1 K | Palisade Capital Management Llc | 2024-12-31 | 503.4 K | Nuveen Asset Management, Llc | 2024-12-31 | 465.5 K | Goldman Sachs Group Inc | 2024-12-31 | 432.8 K | Bank Of America Corp | 2024-12-31 | 403.6 K | Kornitzer Capital Management Inc | 2024-12-31 | 384 K | Blackrock Inc | 2024-12-31 | 2.9 M | Vanguard Group Inc | 2024-12-31 | 1.8 M |
Follow Castle Biosciences' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 585.68 M.Market Cap |
|
Project Castle Biosciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.04 | 0.05 | |
| Return On Capital Employed | 0.02 | 0.02 | |
| Return On Assets | 0.03 | 0.04 | |
| Return On Equity | 0.04 | 0.04 |
When accessing Castle Biosciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Castle Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Castle Biosciences' profitability and make more informed investment decisions.
Evaluate Castle Biosciences' management efficiency
Castle Biosciences has return on total asset (ROA) of 0.011 % which means that it generated a profit of $0.011 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0431 %, meaning that it created $0.0431 on every $100 dollars invested by stockholders. Castle Biosciences' management efficiency ratios could be used to measure how well Castle Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Castle Biosciences' Return On Tangible Assets are quite stable compared to the past year. Return On Capital Employed is expected to rise to 0.02 this year, although the value of Return On Equity will most likely fall to 0.04. At this time, Castle Biosciences' Non Current Assets Total are quite stable compared to the past year. Non Currrent Assets Other is expected to rise to about 2.3 M this year, although the value of Net Tangible Assets will most likely fall to about 181.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 16.41 | 9.22 | |
| Tangible Book Value Per Share | 12.59 | 7.56 | |
| Enterprise Value Over EBITDA | 16.96 | 17.81 | |
| Price Book Value Ratio | 1.62 | 1.71 | |
| Enterprise Value Multiple | 16.96 | 17.81 | |
| Price Fair Value | 1.62 | 1.71 | |
| Enterprise Value | 223.1 M | 198.4 M |
Understanding the operational decisions made by Castle Biosciences management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 0.9603 | Revenue | Quarterly Revenue Growth 0.305 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Castle Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Castle Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Castle Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Castle Biosciences Corporate Filings
| 12th of March 2025 Other Reports | ViewVerify | |
F4 | 11th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 27th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 30th of January 2025 Other Reports | ViewVerify |
Castle Biosciences Earnings Estimation Breakdown
The calculation of Castle Biosciences' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Castle Biosciences is estimated to be -0.0686 with the future projection ranging from a low of -0.31 to a high of 0.1. Please be aware that this consensus of annual earnings estimates for Castle Biosciences is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.31 Lowest | Expected EPS | 0.10 Highest |
Castle Biosciences Earnings Projection Consensus
Suppose the current estimates of Castle Biosciences' value are higher than the current market price of the Castle Biosciences stock. In this case, investors may conclude that Castle Biosciences is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Castle Biosciences' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 9 | -49.87% | 0.32 | -0.0686 | 0.62 |
Castle Biosciences Earnings History
Earnings estimate consensus by Castle Biosciences analysts from Wall Street is used by the market to judge Castle Biosciences' stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Castle Biosciences' upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.Castle Biosciences Quarterly Gross Profit |
|
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Castle Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Castle Biosciences Earnings per Share Projection vs Actual
Actual Earning per Share of Castle Biosciences refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Castle Biosciences predict the company's earnings will be in the future. The higher the earnings per share of Castle Biosciences, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Castle Biosciences Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Castle Biosciences, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Castle Biosciences should always be considered in relation to other companies to make a more educated investment decision.Castle Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Castle Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-26 | 2024-12-31 | 0.04 | 0.32 | 0.28 | 700 | ||
2024-11-04 | 2024-09-30 | -0.06 | 0.08 | 0.14 | 233 | ||
2024-08-05 | 2024-06-30 | -0.27 | 0.31 | 0.58 | 214 | ||
2024-05-02 | 2024-03-31 | -0.33 | -0.09 | 0.24 | 72 | ||
2024-02-28 | 2023-12-31 | -0.54 | -0.1 | 0.44 | 81 | ||
2023-11-02 | 2023-09-30 | -0.76 | -0.26 | 0.5 | 65 | ||
2023-08-02 | 2023-06-30 | -0.91 | -0.7 | 0.21 | 23 | ||
2023-05-03 | 2023-03-31 | -0.89 | -1.1 | -0.21 | 23 | ||
2023-02-28 | 2022-12-31 | -0.84 | -0.78 | 0.06 | 7 | ||
2022-11-02 | 2022-09-30 | -0.88 | -0.77 | 0.11 | 12 | ||
2022-08-08 | 2022-06-30 | -0.76 | -0.06 | 0.7 | 92 | ||
2022-05-09 | 2022-03-31 | -0.71 | -0.97 | -0.26 | 36 | ||
2022-02-28 | 2021-12-31 | -0.47 | -0.25 | 0.22 | 46 | ||
2021-11-08 | 2021-09-30 | -0.4 | -0.47 | -0.07 | 17 | ||
2021-08-09 | 2021-06-30 | -0.37 | -0.34 | 0.03 | 8 | ||
2021-05-10 | 2021-03-31 | -0.23 | -0.17 | 0.06 | 26 | ||
2021-03-08 | 2020-12-31 | -0.12 | -0.17 | -0.05 | 41 | ||
2020-11-09 | 2020-09-30 | -0.11 | -0.23 | -0.12 | 109 | ||
2020-08-10 | 2020-06-30 | -0.4 | -0.19 | 0.21 | 52 | ||
2020-05-11 | 2020-03-31 | -0.15 | 0.03 | 0.18 | 120 | ||
2020-03-10 | 2019-12-31 | -0.2 | 0.11 | 0.31 | 155 | ||
2019-11-11 | 2019-09-30 | -0.3 | 0.05 | 0.35 | 116 | ||
2019-09-03 | 2019-06-30 | -1.36 | -1.05 | 0.31 | 22 | ||
2019-05-29 | 2019-03-31 | 0 | -1.22 | -1.22 | 0 |
Castle Biosciences Corporate Management
| Camilla Zuckero | Exec Communications | Profile | |
| John Abbott | VP Controller | Profile | |
| RN RN | Chief Officer | Profile | |
| Kristen RN | Chief Officer | Profile | |
| Tobin Juvenal | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Castle Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. If investors know Castle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Castle Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.93) | Earnings Share 0.62 | Revenue Per Share | Quarterly Revenue Growth 0.305 | Return On Assets |
The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Castle Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Castle Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Castle Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.